skip to Main Content

Vaccines / Preventive Services

Adult immunization rates are falling short of national targets. Learn how global, federal, and state policies affect vaccination uptake. Leverage our findings to guide your strategies. Rely on our expertise commercializing novel and therapeutic vaccines.

Reducing Funding to WHO May Impact Existing Vaccines Programs

On April 15, President Trump announced his intention to halt funding to the World Health Organization (WHO), pending an investigation into WHO’s response to the COVID-19 pandemic. WHO first declared the outbreak a Public Health Emergency of International Concern on January 30 and a global pandemic on March 11. A reduction in funding from the US could limit WHO’s COVID-19 response activities as well as its regular vaccine programming, including product prequalification, global surveillance, and ongoing efforts to strengthen health systems.

Impact of the COVID-19 Pandemic on Sickle Cell Disease Management

Sickle cell disease (SCD) is a severe red blood cell disorder that disproportionately affects African-American and Hispanic populations. In the United States, there are approximately 100,000 individuals living with SCD (although there is a lack of accurate reporting and the exact number is unknown).

Diagnostic Testing and Patient Screening Are Key to Successful US COVID-19 Response

As the novel coronavirus (COVID-19) spreads throughout the United States, media and policy focus on the rollout of diagnostic testing for the disease has greatly increased. Understanding the role of testing and screening is key to the control of this outbreak.

Considerations for Patient Support Programs in the COVID-19 Era

As the economic and social impact of COVID-19 change how patients access and receive care, manufacturers and third-party suppliers must consider how to evolve their patient support programs to meet the shifting access and affordability needs of patients.

Fred Bently

Podcast: E7 – Get the Facts on COVID-19: Post-Acute Care

Tune into the seventh episode of our series that focuses on COVID-19. In episode 7, Avalere experts from the Health Plans and Provider’s practice discuss the short- and long-term implications for post-acute care as a result of COVID-19.

Patients Using DMARDs for Autoimmune Diseases May Encounter Access Challenges

As COVID-19 deaths increase, the FDA is evaluating and considering approval of treatments more quickly, but the rush to find treatment options is creating new access considerations for patients and providers.

Medicare Part D Plans Continue to Require Cost Sharing for Vaccines

An Avalere analysis finds that Medicare Part D plans allow $0 cost-sharing for select vaccines just 4% of the time, likely affecting immunization uptake.

Thomas Hess

Home Testing Can Keep People Safe and Get Them Back to Work—Here’s How

On April 7, Gillian Woollett authored a Health Affairs blog piece with Ge Bai from the Johns Hopkins Carey Business School and Bruce Pyenson from Milliman about the role that testing plays in recovering from the COVID-19 pandemic.

COVID-19: Future Considerations for Biopharma

As the COVID-19 pandemic unfolds, stakeholders across the healthcare system are facing new realities that will affect the environment in which drugs are commercialized and accessed.

Where We Stand on COVID-19 Treatments

Globally, the need to flatten the epidemic curve of COVID-19 cases has become the top public health priority to save lives and minimize the burden on the health care system. In the absence of treatments and prophylactics for the novel coronavirus, social distancing and quarantine strategies continue to be implemented in the US.

Fred Bently

Webinar: The Impact of COVID-19 on the Health Insurance Industry

Our panel of experts engaged in an in-depth discussion of the rapidly evolving regulatory environment surrounding COVID-19 testing and treatment and the strategic, financial, and operational challenges this disease presents for health insurers.

Alessandra Fix

Ensuring COVID-19 Vaccine Affordability

On March 30, Avalere policy experts published a piece in the Health Affairs blog about the existing programs in place to ensure patient access to affordable COVID-19 vaccines.

Diagnostic Considerations for COVID-19

As the Coronavirus Disease 2019 (COVID-19), caused by the novel SARS-CoV-2 virus, rapidly spreads through the US, media and public scrutiny over the current diagnostic testing landscape has increased, given that the US lags behind other countries in the number of tests performed and turnaround time for results reported.

Podcast: E2 – Get the Facts on COVID-19: Patient Out-of-Pocket Costs

Tune into the second episode of our podcast series that focuses on COVID-19. In episode 2, Avalere experts discuss how Medicare, Medicaid, and commercial plans will address the patient out of pocket costs associated with COVID-19 testing and treatment. They also acknowledge how commercial manufacturers are addressing the shortage of tests and turnaround for COVID-19 testing in the US.

Sign up to receive more insights about Vaccines / Preventive Services
Please enter your email address to be notified when new Vaccines / Preventive Services insights are published.

Back To Top